• Belelli D, Bolger MB, Gee KW. (1989) Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Eur J Pharmacol 166:325329.
  • Claassen J, Hirsch LJ, Emerson RG, Mayer SA. (2002) Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 43:146153.
  • Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. (2013) Predictors of outcome in refractory status epilepticus. JAMA Neurol 70:7277.
  • Holtkamp M, Othman J, Buchheim K, Meierkord H. (2005) Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 76:534539.
  • Kokate TG, Svensson BE, Rogawski MA. (1994) Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 270:12231229.
  • Kokate TG, Cohen AL, Karp E, Rogawski MA. (1996) Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 35:10491056.
  • Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA. (1998) Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J Pharmacol Exp Ther 287:553558.
  • Lonsdale D, Burnham WM. (2007) The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats. Neurosci Lett 411:147151.
  • Lossin C. (2012) Allopregnanolone treatment in a rat pediatric status epilepticus model: comparison with diazepam 2012 American Epilepsy Society Annual Meeting, AES.
  • Lowenstein DH, Alldredge BK. (1993) Status epilepticus at an urban public hospital in the 1980s. Neurology 43:483488.
  • Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. (2002) Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 59:205210.
  • Naylor DE, Liu H, Wasterlain CG. (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25:77247733.
  • Reddy DS, Rogawski MA. (2012) Neurosteroids - endogenous regulators of seizure susceptibility and role in the treatment of epilepsy. In Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds) Jasper's basic mechanisms of the epilepsies. Oxford University Press, New York, pp. 9841002.
  • Rossetti AO, Logroscino G, Bromfield EB. (2005) Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 62:16981702.
  • Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. (2011) A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 14:410.
  • Shorvon S, Ferlisi M. (2011) The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134:28022818.
  • Sutter R, Marsch S, Fuhr P, Ruegg S. (2013) Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia 54:502511.